Clinical trial · Observational
Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC
KETACANCER: Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation…) and administration protocol (route, posology, duration, administration sequence, premedication). The secondary objectives are to evaluate in the context of cancer, the analgesic efficacy, the tolerance profile (biological and clinical toxicities) and the quality of life, including anxiety and depression. In addition, the described parameters will be evaluated as safety and efficacy predictive factors of the Ketamine in oncology.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chronic Pain | — | UNRESOLVED | — |
| Neuropathic Pain | — | UNRESOLVED | — |
| Opioid Use | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ketamine use in CLCC sites (indication and administration protocol) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication
- timeFrame
- Up to 3 months after inclusion
- description
- neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation
- measure
- Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of administration protocol
- timeFrame
- Up to 3 months after inclusion
- description
- route, posology, duration, administration sequence, premedication
Secondary outcomes (6)
- measure
- Evaluate in the context of cancer the antalgic efficacy
- timeFrame
- Up to 3 months after inclusion
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient at least 18 years old at the day of consenting to the study * Patient followed for a solid tumour or a hematological malignancy (treated or under treatment) * Patient presenting cancer chronic pain or post cancer treatment pain * Patient followed by a CLCC's intractable chronic pain consultation or centre * Patient with an indication of 1st Ketamine course: * Analgesic treatment of cancer chronic pain * Analgesic treatment for a post-cancer treatment chronic pain * Help for withdrawal from opioid treatment prescribed for a chronic cancer pain * Patient not previously treated by Ketamine * Patient covered by a medical insurance * Patient and/or family did not decline data collection after complete information (information sheet) Exclusion Criteria: * Patient presenting chronic pains not related to cancer or its treatments * Patient with a proven psychotic history * Patient who is not fluent enough in French
References
Publications (0)
Data not yet available